계명대학교 의학도서관 Repository

A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study

Metadata Downloads
Author(s)
Ung KimChan-Hee LeeJung-Hwan JoHyun-Wook LeeYoon-Jung ChoiJang-Won SonSang-Hee LeeJong-Seon ParkDong-Gu ShinYoung-Jo KimMyung-Ho JeongMyung-Chan ChoJang-Ho BaeJae-Hwan LeeTae-Soo KangKyung-Tae JungKyung-Ho JungSeung-Wook LeeJang-Hyun ChoWon KimSeung-Ho HurKi-Sik KimHeon-Sik ParkMoo-Hyun KimJin-Yong HwangDoo-Il KimTae-Ik Kim
Keimyung Author(s)
Hur, Seung Ho
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of Korean Medical Science
Issued Date
2013
Volume
28
Issue
11
Keyword
Everolimus-Eluting StentPaclitaxel-Eluting Stent
Abstract
We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion evascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n = 425) and PES (n = 425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (P for non-inferiority = 0.021). MACE rates were significantly
different; 5.6% in PES and 2.5% in EES (P = 0.027). Rates of MI (0.8% in PES vs 0.2% in EES, P = 0.308), all deaths (1.5% in PES vs 1.2% in EES, P = 0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES, P = 0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR.
Keimyung Author(s)(Kor)
허승호
Publisher
School of Medicine
Citation
Ung Kim et al. (2013). A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study. Journal of Korean Medical Science, 28(11), 1609–1614. doi: 10.3346/jkms.2013.28.11.1609
Type
Article
ISSN
1011-8934
DOI
10.3346/jkms.2013.28.11.1609
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33794
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.